Structural characterization of a low density lipoprotein receptor-active apolipoprotein E peptide, ApoE3-(126-183).
Apolipoprotein E (apoE) plays a critical role in lipoprotein particle clearance from blood plasma through its interaction with the low density lipoprotein (LDL) receptor and other related receptors. Here, we studied a 58-residue peptide encompassing the receptor binding region of apoE. ApoE3-(126-183) was generated by cyanogen bromide cleavage of recombinant apoE3-(1-183), purified by reversed-phase high pressure liquid chromatography, and characterized by mass spectrometry. Far UV CD spectroscopy of the peptide showed that it is unstructured in aqueous solution. The addition of trifluoroethanol or dodecylphosphocholine induces the peptide to adopt an alpha-helical conformation. ApoE3-(126-183) efficiently transforms dimyristoylphosphatidylglycerol (DMPG) vesicles into peptide-lipid complexes. Analysis of apoE3-(126-183). DMPG complexes by electron microscopy revealed disc-shaped particles with an average diameter of 13 +/- 3 nm. Flotation equilibrium analysis yielded a particle molecular mass of 252 kDa. Far UV CD analysis of apoE3-(126-183).DMPG discs provided evidence that the peptide adopts a helical conformation. Competition binding experiments with (125)I-labeled low density lipoprotein (LDL) were conducted to assess the ability of apoE3-(126-183).DMPG complexes to bind to the LDL receptor. Both N-terminal apoE and the peptide, when complexed with DMPG, competed with (125)I-LDL for binding sites on the surface of cultured human skin fibroblasts. Under the conditions employed, apoE3-(126-183).DMPG complexes were similar to apoE3-(1-183).DMPG discs in their ability to bind to the receptor, demonstrating that the peptide represents a good model to study the interaction between apoE and the LDL receptor. Preliminary NMR results indicated that a high resolution structure of the apoE3-(126-183) peptide is obtainable.
Raussens
V
V
Lipid Biology Research Group and Protein Engineering Network of Centres of Excellence, Department of Biochemistry, University of Alberta, 327 HMRC, Edmonton, Alberta T6G 2S2, Canada. raussens@ualberta.ca
Mah
M K
MK
Kay
C M
CM
Sykes
B D
BD
Ryan
R O
RO
D053318:Apolipoprotein E3; D001057:Apolipoproteins E / Q000737:chemistry* / Q000494:pharmacology*; D001667:Binding, Competitive; D002478:Cells, Cultured; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D008077:Lipoproteins, LDL / Q000378:metabolism; D008081:Liposomes / Q000737:chemistry; D010446:Peptide Fragments / Q000737:chemistry* / Q000494:pharmacology; D010715:Phosphatidylglycerols / Q000737:chemistry; D017433:Protein Structure, Secondary; D011973:Receptors, LDL / Q000187:drug effects / Q000378:metabolism*; D011994:Recombinant Proteins / Q000737:chemistry / Q000494:pharmacology; D012867:Skin / Q000378:metabolism
D053318:Apolipoprotein E3; D001057:Apolipoproteins E; D008077:Lipoproteins, LDL; D008081:Liposomes; D010446:Peptide Fragments; D010715:Phosphatidylglycerols; D011973:Receptors, LDL; D011994:Recombinant Proteins; C002773:dimyristoylphosphatidylglycerol